Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on February 16, 2022, the Company granted nine new employees options to purchase a total of 189,400 shares of the Company’s common stock at an exercise price per share equal to $4.08, which was the closing trading price on February 15, 2022, the date of the grant.
The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About CytomX Therapeutics, Inc.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
VP, Investor Relations & Corp. Communications
Direct: (650) 273-4999
Director, Corporate Communications
Direct: (650) 528 2929